Search Share Prices
AZN Headlines - AstraZeneca (AZN) Given “Sell” Rating at Goldman Sachs Group
AstraZeneca (LON:AZN)‘s stock had its “sell” rating reissued by equities research analysts at Goldman Sachs Group in a research note issued to investors on Monday, March 18th. Other analysts also ...
AstraZeneca wins regulatory approval for Europe's first type-1 diabetes drug taken by mouth
AstraZeneca PLC (LON:AZN) has won regulatory approval for a breakthrough diabetes drug with its new product Forxiga becoming the first oral treatment for the type-1 form of the disease in Europe. It ...
AstraZeneca’s (AZN) Hold Rating Reaffirmed at Liberum Capital
Liberum Capital reissued their hold rating on shares of AstraZeneca (LON:AZN) in a report published on Wednesday morning. Other equities analysts also recently issued reports about the company. ...
FTSE 100 watch: Footsie builds on gains as investors eye Fed meeting
In individual FTSE 100 company news, shares in AstraZeneca (LON:AZN) have been steady as the US regulator granted orphan drug designation (ODD) to a potential new respiratory treatment.
AstraZeneca (LON:AZN) price target raised to GBX 5,000 by Goldman Sachs Group
Today, Goldman Sachs Group raised its price target on AstraZeneca (LON:AZN) to GBX 5,000 per share. There are 13 Buy Ratings, 7 Hold Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.